
|Articles|November 1, 2003
BPH management: New paradigms, new approaches
Author(s)Steven A. Kaplan, MD
The paradigm for the medical management of benign prostatic hyperplasia has undergone a significant change during the past decade. Guided by new research, the approval of novel pharmaceutical and minimally invasive therapies, and the economics of health care financing, physicians have altered their approach to patient care in distinct ways.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












